在生物标志物验证的阿尔茨海默氏症病理学患者中,Apraxic缺陷预测了一般认知障碍
Claudia C Schmidt1, Michella M Bardakan2, Elena Jaeger3
1Cognitive Neuroscience, Institute of Neurosciences and Medicine (INM-3), Forschungszentrum Jülich, Jülich, Germany. c.schmidt@fz-juelich.de.
Journal of neurology
|September 25, 2025
概括
阿普拉西亚,或熟练运动的困难,在阿尔茨海默病 (AD) 中很常见. 实践缺陷显著预测认知能力下降,这表明无动于衷可能有助于早期AD诊断.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 认知科学 认知科学
背景情况:
- 失调症是阿尔茨海默病 (AD) 的一个公认的症状,与来自粉样质斑块和tau的神经退行有关.
- 在阿尔茨海默病患者中对阿普拉克斯缺陷的系统性表征是有限的.
- 对阿尔茨海默氏症病理学的生物标志物验证对于准确的患者分层至关重要.
研究的目的:
- 在生物标志物验证的阿尔茨海默氏病理病理的患者中全面调查无动症概况.
- 确定阿普拉西克缺陷和一般认知障碍之间的关系.
- 探讨阿普拉克西亚评估作为阿尔茨海默病早期诊断标准的潜力.
主要方法:
- 采用了一系列标准化的厌食症测试来评估生物标志物验证的阿尔茨海默氏病理 (n=63) 的患者.
- 采用分层回归分析来将人口统计学变量和无力度得分与一般认知障碍相关联.
- 比较模仿手指和手势的表现,以及单个和复杂的手动.
主要成果:
- 在67%的生物标志物验证的阿尔茨海默氏症病理学患者中发现了Apraxic缺陷.
- 患者在模仿手指手势 (89.2%) 和手势 (80.0%) 以及复杂的手动 (97.4%) 和单手动 (78.5%) 中表现出更大的障碍.
- 性评估解释了痴呆症严重程度差异的60%,特定的子测试 (KAS,DATE) 是认知障碍的重要预测因素.
结论:
- 实践缺陷在阿尔茨海默病中非常重要,即使在控制一般认知障碍时也是如此.
- 厌恶症评估,特别是模仿物体使用和肢体厌恶症测试,显著预测了阿尔茨海默氏症患者的一般认知障碍.
- 阿普拉西亚需要进一步调查,因为它可能是阿尔茨海默病的早期诊断标志物.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
